Contact

Rifencin

Gastrointestinal Disorders

Rifencin is a natural product designed for the relief of gastro-intestinal disorders (IBD / IBS)

Its patented formula, combining a bio-optimized extract of turmeric and sweet fennel essential oil, considerably improves all the aspects of the quality of life of the patients with functional gastrointestinal disorders and can be used for long periods without digestive complications.

 

Back to products

Formulation

RIFENCIN Gelatin softgel capsule (size 10 oval) : gelatin soft capsule of 920 mg containing a quantity of turmeric extract corresponding to 42.0 mg of curcumin in highly bioactive form and 25 mg of sweet fennel essential oil.

Clinical Data

RIFENCIN and GI Disease

RIFENCIN is a natural remedy whose active principals act on the symptoms of gastro-intestinal disorders like Irritable Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). The combination of curcumin and fennel offers a combination of complementary active principals.

Curcumin is known in traditional medicine for its capacity to increase bile production, to help relieve the symptoms of indigestion :

  • feeling of "full stomach"
  • flatulence
  • slow digestion

Fennel is also traditionally known for the symptomatic treatment of :

  • mild gastrointestinal spastic disorders
  • flatulence
  • bloating

RIFENCIN is delivered with a complete package of information, including bioXtract proprietary:

  • Pre-clinical acute oral toxicity trial in rats showing no particular effect and classifying the product in the danger 5 category DL50 superior 5,000 mg/kg,
  • Phase I clinical trial demonstrating bioavailability of RIFENCIN's active principals. (Complete report available on request),
  • Phase II randomised, double-blind, multicentre, placebo controlled clinical trial evaluating the efficacy of RIFENCIN in 120 patients suffering from functional gastrointestinal symptoms on a period of 30 days,
  • Observational clinical study, prospective, not-randomized, real-life of RIFENCIN on 253 patients suffering from Intestinal Bowel Syndrome (IBS)

See slides hereunder for more information.

 

 

Phase II randomised, double-blind, multicentre, placebo controlled clinical trial evaluating the efficacy of RIFENCIN in 120 patients suffering from functional gastrointestinal symptoms on a period of 30 days

  • RIFENCIN was significantly superior to placebo in reducing functional gastrointestinal symptoms
  • A significantly higher number of patients in the RIFENCIN group had symptom remission, compared to the placebo group
  • Symptoms improvement in significantly higher in RIFENCIN group at each assesement Day (day 10, 20, 30)
  • RIFENCIN improves all aspects of Quality of Life in patients with functional gastrointestinal disorders
  • RIFENCIN has an excellent safety profile

 

Observational clinical study, prospective, not-randomized, real-life of RIFENCIN on 253 patients suffering from Intestinal Bowel Syndrome (IBS)

 

 

 

Back to products